ESR1 and breast cancer: Another approach is to target AKTpathway by these histone deacetylase inhibitors, which have beenapproved by the U.S. Food and Drug Administration (FDA) fortreating a rare type of lymphoma, as AKT helps in proliferationof cells in normal condition but in breast cancer it maybe beelevated and allows cancer cells to use ER in the presence oftamoxifen [26].